Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group

Rebabonye B. Pharithi,Deepti Ranganathan,Jim O’Brien,Emmanuel E. Egom,Cathie Burke,Daniel H. Ryan,Christine McAuliffe,Marguerite Vaughan,Tara Coughlan,Edwina Morrissey,John C. McHugh,David Moore,Ronan Collins

Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group

2019

Rebabonye B. Pharithi
Deepti Ranganathan
Jim O’Brien
Emmanuel E. Egom
Cathie Burke
Daniel H. Ryan
Christine McAuliffe
Marguerite Vaughan
Tara Coughlan
Edwina Morrissey
John C. McHugh
David Moore
Ronan Collins

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are a major advance for stroke prevention in atrial fibrillation (AF). Use of the vitamin K antagonist (VKA), warfarin, has dropped 40% since 2010 in our institution. There is limited Irish hospital data on NOAC prescribing for stroke prevention.

Keywords:

Cardiology
Surgery
Vitamin
Anticoagulant
Atrial fibrillation
Vitamin K antagonist
Medical prescription
Internal medicine
Diabetes mellitus
Warfarin
Stroke
Medicine
Dabigatran
Rivaroxaban
Apixaban

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations